DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ERIS LIFESCIENCES LIMITED (ERIS) share price today?

ERIS LIFESCIENCES LIMITED (ERIS) is trading at ₹1,455.4 on the NSE, down 2.22% on the day. Source: DocStoX.

What is the PE ratio of ERIS LIFESCIENCES LIMITED?

ERIS LIFESCIENCES LIMITED has a price-to-earnings (PE) ratio of 32.5 in the Healthcare sector.

What is the market capitalisation of ERIS LIFESCIENCES LIMITED?

ERIS LIFESCIENCES LIMITED has a market capitalisation of approximately ₹20,154 crore.

ERIS LIFESCIENCES LIMITED

ERIS·NSE·Healthcare

₹1,455.40▼ -33.00 (-2.22%)

Healthcare · Pharmaceuticals

Revenue compounding 23% a year

NIFTY 500NIFTY SMALLCAP 250

Day₹1441.20

₹1495.90

52W₹1200

₹188537%

Open

₹1495.90

High

₹1495.90

Low

₹1441.20

Prev Close

₹1488.40

Volume

77.0K

VWAP

₹1455.13

Snapshot

Key fundamentals

Market Cap

₹20,154 Cr

P/E Ratio

32.54Fair

P/B Ratio

5.14

EPS

₹44.72

Book Value

₹282.00

ROE

18.70%Strong

ROCE

14.00%Decent

Dividend Yield

0.50%

Debt / Equity

0.60Moderate

Face Value

₹1.00

52W High

₹1885.00

52W Low

₹1200.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹401

▼ 72.5%downside

Trading at ₹1,455 — 72% above our estimate

BearFair valueBull

₹341₹401₹533

/100

Business quality — Solid

Growth 86Profitability 84Efficiency 15Valuation 57

Plain English

Our view

Revenue compounding 23% a year
Revenue compounding 23% over 3 years
Fundamental red flags (Piotroski 1/9)

Strengths

Revenue compounding 23% over 3 years
Profit growing 20% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

19% ROE fading to 13% over ~10 yrs, on ₹282 book

₹364

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹533

Analyst target

No analyst coverage

—

Blended fair value₹401

What the numbers say

Investment thesis

Bull case

Revenue compounding 23% over 3 years
Profit growing 20% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

32.5Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

18.7%Strong

Above 15% is considered healthy for Indian equities

ROCE

14.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.60Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹20,154 Cr

P/B

5.14

EPS

₹44.72

Div Yield

0.50%

What changed

Recent changes

Foreign investors-0.6% stake last quarter
Domestic institutions+0.4% stake last quarter
Promoters+0.22% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 32.5×

Growth

Strong

+23% rev CAGR

Profitability

Excellent

18.7% ROE

Financial health

Comfortable

D/E 0.60

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.2%

Turnover₹1121.04L Cr

Trades15,501

VWAP₹1455.13

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+22.9%

+20.9%

10Y

+18.0%

Profit

+20.1%

+12.8%

10Y

+17.0%

EPS

+16.8%

+11.3%

10Y

-41.6%

Profile

Cons

Stock is trading at 5.08 times its book value
Promoter holding has decreased over last quarter: -0.93%
Tax rate seems low

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters raised their stake by 0.22 pts; foreign investors sold 0.63 pts; domestic institutions added 0.36 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

54%

Promoter

Promoters

54.1%+0.22

Public

19.4%+0.06

FII / FPI

5.8%-0.63

DII

20.7%+0.36

Quarterly trend

Ownership over time

Q1 FY27

Promoter54.14%

FII5.76%

DII20.71%

Public19.39%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]